Nilo Therapeutics launched with $101 million in Series A financing to develop therapies that modulate specific neural circuits to restore immune homeostasis. The New York‑based company was founded by researchers from Columbia, Yale and Harvard (Charles Zuker, Ruslan Medzhitov, Steve Liberles) and intends to translate mechanistic neuro‑immunology into drugs for autoimmune and inflammatory diseases. The round was led by The Column Group, DCVC Bio and Lux Capital, with contributions from the Gates Foundation and Alexandria Venture Investments. CEO Kim Seth and CSO Laurens Kruidenier plan to use proceeds to establish labs, expand R&D teams and progress preclinical programs that act on vagal and other regulatory neurons identified in foundational academic work. Nilo’s approach—targeting ‘master regulator’ brain‑body circuits—represents a shift toward neuromodulatory pharmacology for systemic immune control and joins a growing cohort of companies pursuing neuro‑immune axes as therapeutic targets.